Bessemer Group
AXSM icon

Bessemer Group’s Axsome Therapeutics AXSM Stock Holding History

Bessemer Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69K Sell
283
-1,145
-80% -$248K ﹤0.01% 1609
2026
Q1 		$242K Sell
1,428
-8
-0.6% -$1.38K ﹤0.01% 1349
2025
Q4 		$262K Buy
1,436
+21
+1% +$2.93K ﹤0.01% 1300
2025
Q3 		$172K Buy
1,415
+1,280
+948% +$144K ﹤0.01% 1159
2025
Q2 		$14K Buy
135
+110
+440% +$11.6K ﹤0.01% 1673
2025
Q1 		$3K Sell
25
-5
-17% -$570 ﹤0.01% 2131
2024
Q4 		$3K Hold
30
– – ﹤0.01% 2109
2024
Q3 		$3K Buy
+30
New +$2.62K ﹤0.01% 2063

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bessemer Group's AXSM Position: Q2 2026 in Review

Bessemer Group reduced its Axsome Therapeutics (AXSM) stake by 80% in Q2 2026, selling an estimated $248K and leaving 283 shares worth $69K. The position accounts for ﹤0.01% of the portfolio, ranked #1609.

Bessemer Group first reported a position in AXSM in Q3 2024 and has held it in 8 quarters since. The position peaked at $262K in Q4 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Bessemer Group held 283 shares of Axsome Therapeutics worth $69K as of Q2 2026.
  • Bessemer Group sold 1,145 Axsome Therapeutics shares in Q2 2026, an estimated $248K.
  • Axsome Therapeutics made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #1609 holding.
  • Bessemer Group first reported a position in Axsome Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Bessemer Group's Axsome Therapeutics position peaked at $262K in Q4 2025.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.